Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP827107.RACqx1Z-mWNZxTMXJGMvGezRYgaOoARpXJBzrZKX27Myk130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827107.RACqx1Z-mWNZxTMXJGMvGezRYgaOoARpXJBzrZKX27Myk130_provenance.
• NP198760.RAnJT41iSrr7BobiCsewCW1w18jPQvcpplPQThtWmY9B4130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP198760.RAnJT41iSrr7BobiCsewCW1w18jPQvcpplPQThtWmY9B4130_provenance.
• NP934299.RAfk3fanwaNLPWSWCXRhbFlinFI8ZzTUFuuGDEwd911is130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP934299.RAfk3fanwaNLPWSWCXRhbFlinFI8ZzTUFuuGDEwd911is130_provenance.
• NP626747.RAfGt2J69em7VmBnv-MVrlIhgqJ-Td5lX5RO1ieqPPEG8130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP626747.RAfGt2J69em7VmBnv-MVrlIhgqJ-Td5lX5RO1ieqPPEG8130_provenance.
• NP624382.RAdVIu8oNqzOUwqR4JcCNd9zQtZtpTimbBG6glrh6WzaE130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624382.RAdVIu8oNqzOUwqR4JcCNd9zQtZtpTimbBG6glrh6WzaE130_provenance.
• assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP903621.RANKnr_FzRxjYoz8kQkmPV9QO5y3M2BuFeL4pn3o24yA4130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP903621.RANKnr_FzRxjYoz8kQkmPV9QO5y3M2BuFeL4pn3o24yA4130_provenance.
• NP720969.RACIWcq-_9xh340W38wIHxj5Yuvz8DIMBpy_0GG1pnaAQ130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP720969.RACIWcq-_9xh340W38wIHxj5Yuvz8DIMBpy_0GG1pnaAQ130_provenance.
• NP720971.RAgy6txU-F7KctNl8EM0vza5A7TzuUrYYSdESUrQrJmF4130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP720971.RAgy6txU-F7KctNl8EM0vza5A7TzuUrYYSdESUrQrJmF4130_provenance.
• NP621855.RAOJVfGdPcV_suqxTVzwTj4tjZrrARF9CWuCdL3txuT0I130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621855.RAOJVfGdPcV_suqxTVzwTj4tjZrrARF9CWuCdL3txuT0I130_provenance.
• NP625522.RAMOusdFGJqQBjqY-rr0KDE4L7kClloxtiHaX-f_Kn3jo130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625522.RAMOusdFGJqQBjqY-rr0KDE4L7kClloxtiHaX-f_Kn3jo130_provenance.
• NP623067.RA8kIHPsXXJQnySVG6XoAEnWRSpHjHQC8moVaMO4kdm9g130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623067.RA8kIHPsXXJQnySVG6XoAEnWRSpHjHQC8moVaMO4kdm9g130_provenance.
• NP720975.RAGVg5Bi0mYsetNBHn4Pytq77uYl-ggiUEEjgv5WkpR3k130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP720975.RAGVg5Bi0mYsetNBHn4Pytq77uYl-ggiUEEjgv5WkpR3k130_provenance.
• NP720970.RA4FiJcc7-jXScRl8tG5zH4qmMhJcgJDeLzE6_xniL8xw130_assertion description "[This work suggests that multilevel inhibition of the PI3K/Akt/mTOR pathway and double-block of cell cycle progression are effective strategies for DLBCL therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP720970.RA4FiJcc7-jXScRl8tG5zH4qmMhJcgJDeLzE6_xniL8xw130_provenance.